Phenformin-loaded polymeric micelles for targeting both cancer cells and cancer stem cells invitro and invivo

Biomaterials

Volumn 35, Issue 33, 2014, Pages 9177-9186

  Krishnamurthy, Sangeetha ^a   Ng, Victor W L ^a   Gao, Shujun ^a   Tan, Min Han ^a   Yang, Yi Yan ^a  

^a INSTITUTE OF BIOENGINEERING AND NANOTECHNOLOGY   (Singapore)

Author keywords

Cancer stem cells; Invivo efficacy; Lung cancer; Phenformin; Polymeric micelles

Indexed keywords

BIOLOGICAL ORGANS; BLOCK COPOLYMERS; CELL CULTURE; CHEMOTHERAPY; HYDROGEN BONDS; MICELLES; PATHOLOGY; POLYCARBONATES; POLYETHYLENE GLYCOLS; POLYETHYLENE OXIDES; POLYMERS; RESPIRATORY SYSTEM; STEM CELLS; UREA;

CANCER STEM CELLS; IN-VIVO; LUNG CANCER; PHENFORMIN; POLYMERIC MICELLE;

DISEASES;

COPOLYMER; MACROGOL; PHENFORMIN; POLYCARBONATE; POLYMER; ANTINEOPLASTIC AGENT; MACROGOL DERIVATIVE; MICELLE; POLYCARBOXYLATE CEMENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER STEM CELL; CELL GROWTH; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG RELEASE; DRUG TARGETING; FEMALE; GEL PERMEATION CHROMATOGRAPHY; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG CANCER; LUNG CANCER CELL LINE; MICELLE; MOUSE; MTS ASSAY; NONHUMAN; OXYGEN CONSUMPTION; POLYMERIZATION; PRIORITY JOURNAL; ANIMAL; BAGG ALBINO MOUSE; CHEMISTRY; DRUG EFFECTS; DRUG SCREENING; LIVER; METABOLISM; NUDE MOUSE; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; FEMALE; HUMANS; LIVER; MICE; MICE, INBRED BALB C; MICE, NUDE; MICELLES; NEOPLASTIC STEM CELLS; PHENFORMIN; POLYCARBOXYLATE CEMENT; POLYETHYLENE GLYCOLS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84906782604     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2014.07.018     Document Type: Article

References (46)

1. Wang Y., Zhang X., Yu P., Li C. Glycopolymer micelles with reducible ionic cores for hepatocytes-targeting delivery of DOX. Int J Pharm 2013, 441:170-180.
2. Hanna N., Shepherd F.A., Fossella F.V., Pereira J.R., De Marinis F., von Pawel J., et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. JClin Oncol 2004, 22:1589-1597.
3. Creutzberg C.L., van Putten W.L., Koper P.C., Lybeert M.L., Jobsen J.J., Wárlám-Rodenhuis C.C., et al. Survival after relapse in patients with endometrial cancer: results from a randomized trial. Gynecol Oncol 2003, 89:201-209.
4. Cirocco W.C., Schwartzman A., Golub R.W. Abdominal wall recurrence after laparoscopic colectomy for colon cancer. Surgery 1994, 116:842-846.
5. Alamgeer M., Peacock C.D., Matsui W., Ganju V., Watkins D.N. Cancer stem cells in lung cancer: evidence and controversies. Respirology 2013, 18:757-764.
6. Pine S.R., Marshall B., Varticovski L. Lung cancer stem cells. Dis Markers 2008, 24:257-266.
7. Ho M.M., Ng A.V., Lam S., Hung J.Y. Side population in human lung cancer cell lines and tumors is enriched with stem-like cancer cells. Cancer Res 2007, 67:4827-4833.
8. Reya T., Morrison S.J., Clarke M.F., Weissman I.L. Stem cells, cancer, and cancer stem cells. Nature 2001, 414:105-111.
9. Eramo A., Lotti F., Sette G., Pilozzi E., Biffoni M., Di Virgilio A., et al. Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ 2007, 15:504-514.
10. Wicha M.S., Liu S., Dontu G. Cancer stem cells: an old idea-a paradigm shift. Cancer Res 2006, 66:1883-1890.
11. Eyler C.E., Rich J.N. Survival of the fittest: cancer stem cells in therapeutic resistance and angiogenesis. JClin Oncol 2008, 26:2839-2845.
12. Jiang F., Qiu Q., Khanna A., Todd N.W., Deepak J., Xing L., et al. Aldehyde dehydrogenase 1 is a tumor stem cell-associated marker in lung cancer. Mol Cancer Res 2009, 7:330-338.
13. Levina V., Marrangoni A.M., DeMarco R., Gorelik E., Lokshin A.E. Drug-selected human lung cancer stem cells: cytokine network, tumorigenic and metastatic properties. PLoS One 2008, 3:e3077.
14. Bao S., Wu Q., McLendon R.E., Hao Y., Shi Q., Hjelmeland A.B., et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006, 444:756-760.
15. Rich J.N. Cancer stem cells in radiation resistance. Cancer Res 2007, 67:8980-8984.
16. Hirsch H.A., Iliopoulos D., Tsichlis P.N., Struhl K. Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res 2009, 69:7507-7511.
17. Ailles L.E., Weissman I.L. Cancer stem cells in solid tumors. Curr Opin Biotechnol 2007, 18:460-466.
18. Sachlos E., Risueño R.M., Laronde S., Shapovalova Z., Lee J.-H., Russell J., et al. Identification of drugs including a dopamine receptor antagonist that selectively target cancer stem cells. Cell 2012, 149:1284-1297.
19. Bednar F., Simeone D.M. Metformin and cancer stem cells: old drug, new targets. Cancer Prev Res 2012, 5:351-354.
20. Pan J.-X., Ding K., Wang C.-Y. Niclosamide, an old antihelminthic agent, demonstrates antitumor activity by blocking multiple signaling pathways of cancer stem cells. Chin J Cancer 2012, 31:178-184.
21. Schäfer G. Biguanides. A review of history, pharmacodynamics and therapy. Diabete Metab 1983, 9:148-163.
22. Zakikhani M., Dowling R., Fantus I.G., Sonenberg N., Pollak M. Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res 2006, 66:10269-10273.
23. Dilman V., Anisimov V. Effect of treatment with phenformin, diphenylhydantoin or L-dopa on life span and tumour incidence in C3H/Sn mice. Gerontology 1980, 26:241-246.
24. Lalau J.-D., Race J.-M. Lactic acidosis in metformin-treated patients. Drug Saf 1999, 20:377-384.
25. Huang X., Wullschleger S., Shpiro N., McGuire V., Sakamoto K., Woods Y., et al. Important role of the LKB1-AMPK pathway in suppressing tumorigenesis in PTEN-deficient mice. Biochem J 2008, 412:211-221.
26. Crofford O.B. Metformin. NEngl J Med 1995, 333:588-589.
27. McGuinness M., Talbert R. Phenformin-induced lactic acidosis: a forgotten adverse drug reaction. Ann Pharmacother 1993, 27:1183-1187.
28. Maeda H., Wu J., Sawa T., Matsumura Y., Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. JControl Release 2000, 65:271-284.
29. Yang C., Tan J.P., Cheng W., Attia A.B.E., Ting C.T.Y., Nelson A., et al. Supramolecular nanostructures designed for high cargo loading capacity and kinetic stability. Nano Today 2010, 5:515-523.
30. Ebrahim Attia A.B., Yang C., Tan J.P., Gao S., Williams D.F., Hedrick J.L., et al. The effect of kinetic stability on biodistribution and anti-tumor efficacy of drug-loaded biodegradable polymeric micelles. Biomaterials 2013, 34:3132-3140.
31. Ke X.Y., Lin Ng V.W., Gao S.-J., Tong Y.W., Hedrick J.L., Yang Y.Y. Co-delivery of thioridazine and doxorubicin using polymeric micelles for targeting both cancer cells and cancer stem cells. Biomaterials 2014, 35:1096-1108.
32. Quint L.E., Tummala S., Brisson L.J., Francis I.R., Krupnick A.S., Kazerooni E.A., et al. Distribution of distant metastases from newly diagnosed non-small cell lung cancer. Ann Thorac Surg 1996, 62:246-250.
33. Yang C., Ebrahim Attia A.B., Tan J.P.K., Ke X., Gao S., Hedrick J.L., et al. The role of non-covalent interactions in anticancer drug loading and kinetic stability of polymeric micelles. Biomaterials 2012, 33:2971-2979.
34. Hirschmann-Jax C., Foster A., Wulf G., Nuchtern J., Jax T., Gobel U., et al. Adistinct "side population" of cells with high drug efflux capacity in human tumor cells. Proc Natl Acad Sci U S A 2004, 101:14228-14233.
35. Levchenko T.S., Rammohan R., Lukyanov A.N., Whiteman K.R., Torchilin V.P. Liposome clearance in mice: the effect of a separate and combined presence of surface charge and polymer coating. Int J Pharm 2002, 240:95-102.
36. Yoo H.S., Park T.G. Biodegradable polymeric micelles composed of doxorubicin conjugated PLGA-PEG block copolymer. JControl Release 2001, 70:63-70.
37. Xiangyang X., Ling L., Jianping Z., Shiyue L., Jie Y., Xiaojin Y., et al. Preparation and characterization of N-succinyl-N'-octyl chitosan micelles as doxorubicin carriers for effective anti-tumor activity. Colloids Surf B 2007, 55:222-228.
38. Eramo A., Lotti F., Sette G., Pilozzi E., Biffoni M., Di Virgilio A., et al. Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ 2008, 15:504-514.
39. Golestaneh N., Mishra B. TGF-β, neuronal stem cells and glioblastoma. Oncogene 2005, 24:5722-5730.
40. Oft M., Peli J., Rudaz C., Schwarz H., Beug H., Reichmann E. TGF-beta1 and Ha-Ras collaborate in modulating the phenotypic plasticity and invasiveness of epithelial tumor cells. Genes Dev 1996, 10:2462-2477.
41. Cufí S., Vazquez-Martin A., Oliveras-Ferraros C., Martin-Castillo B., Joven J., Menendez J.A. Metformin against TGF β-induced epithelial-to-mesenchymal transition (EMT): from cancer stem cells to aging-associated fibrosis. Cell Cycle 2010, 9:4461-4468.
42. Hwang Y.P., Jeong H.G. Metformin blocks migration and invasion of tumour cells by inhibition of matrix metalloproteinase-9 activation through a calcium and protein kinase Cα-dependent pathway: phorbol-12-myristate-13-acetate-induced/extracellular signal-regulated kinase/activator protein-1. Br J Pharmacol 2010, 160:1195-1211.
43. Cerezo M., Tichet M., Abbe P., Ohanna M., Lehraiki A., Rouaud F., et al. Metformin blocks melanoma invasion and metastasis development in AMPK/p53-dependent manner. Mol Cancer Ther 2013, 12:1605-1615.
44. Sakamoto K., Göransson O., Hardie D.G., Alessi D.R. Activity of LKB1 and AMPK-related kinases in skeletal muscle: effects of contraction, phenformin, and AICAR. Am J Physiol Endocrinol Metab 2004, 287:310-317.
45. Liu L., Ulbrich J., Müller J., Wüstefeld T., Aeberhard L., Kress T.R., et al. Deregulated MYC expression induces dependence upon AMPK-related kinase 5. Nature 2012, 483:608-612.
46. Owen M., Doran E., Halestrap A. Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem J 2000, 348:607-614.